Navigation Links
BioLife Solutions Products Now Used in More than 50 Clinical Trial-Stage Cellular Therapies
Date:10/29/2012

BOTHELL, Wash., Oct. 29, 2012 /PRNewswire/ -- BioLife Solutions, Inc. (OTCBB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer, today announced the Company's novel biopreservation technology is being used in more than 50 clinical trial-stage cellular therapies, making it the leading choice in the emerging, high growth field of regenerative medicine. Management believes that the Company holds the number one supplier position among companies offering pre-formulated cell and tissue storage and freeze media used in clinical trial stage cellular therapies to treat the leading causes of death and disability such as cancer, heart disease, stroke, and joint/movement disorders.

(Photo:  http://photos.prnewswire.com/prnh/20121029/LA01346-INFO)

(Logo:  http://photos.prnewswire.com/prnh/20090814/BIOLIFELOGO)

BioLife Chief Executive Officer Mike Rice indicated that the Company's revenue from its growing regenerative medicine customer base, along with its selective targeting of contract manufacturing customers, should generate cash and profits in the interim until some regenerative medicine customers gain approval and adoption. At that point, profitable growth should accelerate in a step-wise fashion.

Rice commented: "We've built a very strong franchise for HypoThermosol® and CryoStor®
'/>"/>

SOURCE BioLife Solutions, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology news :

1. BioLife Solutions Announces 7th Consecutive Quarter of Record Revenue
2. Advanced Clinical Joins MedNet Solutions iMedNet Partner Program
3. Statistics & Data Corporation Selects MedNet Solutions As Strategic Technology Partner
4. CEVA, Rubidium Partner to Deliver Speech Processing Solutions based on the CEVA-TeakLite Family of DSPs
5. Novetta Solutions Acquires International Biometric Group, LLC
6. MedNet Solutions Announces Latest Enhancements To Its iMedNet EDC eClinical Solution
7. uAttend Time Tracking Solutions Available at TimeClockDeals.com
8. Validity CTO to Present Natural ID Solutions for Improving Mobile Risk Management and User Experience at NFC Solutions Summit 2012
9. CDS Monarch Deploys DigitalPersona Strong Authentication Solutions for Secure Access to Electronic Medical Records
10. University of Minnesota startup offers game-changing energy solutions that reduce CO2 emissions
11. MedNet Solutions to Demonstrate Its Innovative Suite of eClinical Solutions at the 2012 Bio-IT World Conference & Expo
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... has transformed the energy landscape in the U.S., ... conflict among the energy industry, residents and agricultural ... add that degraded water quality is a potential ... article appears in the ACS journal Environmental ... and colleagues point out that a major criticism ...
(Date:4/23/2014)... the family of bacteria that causes whooping cough ... surprising findings about the bacteria,s origin and evolution. ... to control this respiratory disease, which kills 195,000 ... 343 strains of the Bordetella pertussis ... last 100 years illustrates how vaccination has shaped ...
(Date:4/23/2014)... quickly. It involves visual searching for clues to ... Similarly to humans, biological systems are sometimes under ... that need to be read quickly are usually ... easier it will be to read them quickly. ... Portugal) and Centre for Molecular and Structural Biomedicine ...
Breaking Biology News(10 mins):How to avoid water wars between 'fracking' industry and residents 2Impact of whooping cough vaccination revealed 2Cell division speed influences gene architecture 2
... is nicknamed "yellowcake" for its color and powdered consistency. ... , The yellow monster surfaced on the Navajo Nation ... continued for the next several decades. In its aftermath ... and worries about environmental contamination among people who live ...
... one day precisely release drugs and vaccines inside the ... study, by researchers at Ghent University and the Universit? ... Jan. 9, 2006, print issue of the American Chemical ... other microcapsules, which release their drug cargo only when ...
... study is being published in an advance online version of ... XPB helicase from an archaea, a single cell organism similar ... strands of the nucleic acid double helix, an action that ... well as other cell processes. , "XPB was initially ...
Cached Biology News:Study may help slay 'Yellow Monster' 2Study may help slay 'Yellow Monster' 3Enzyme crystal structure reveals 'unexpected' genome repair functions 2
(Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, April ... Location: Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... nonprofit organization solely dedicated to finding a cure for hepatitis ... worldwide, will host its annual Crystal Ball on Friday, April ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 EquitiesIQ, a ... Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company ... the wound care market. , Free report download: ... with a seasoned management team and Board, which launched ...
(Date:1/14/2014)... 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology ... therapies addressing major unmet medical needs using RNA-targeted ... of Allowance from the United States Patent and ... (sd-rxRNA®), for the treatment of fibrosis. The patent ...
(Date:1/14/2014)... During the 1600’s through the 1800’s doctors ... Plague.” In this time period, doctors did not know that ... to the death of vulnerable patients. In the same way, ... may be unwittingly transmitting herpes viruses to their patients. The ...
Breaking Biology Technology:Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3
... 21, 2009) A faster tool for cell programming and ... have won grand prizes of the 2009 Collegiate Inventors Competition, ... by the Abbott Fund, the non-profit foundation of the global ... Trademark Office (USPTO). Harris Wang, who invented a new ...
... Myriant Technologies LLC (Myriant), a privately-held, biotech developer ... of its Science Advisory Board and the appointment ... collectively will provide broad insight into all aspects ... biomass feedstocks into valuable chemicals. , (Logo: ...
... N.J. and WALTHAM, Mass., Oct. 21 BioWa, ... today that they have entered into an agreement ... POTELLIGENT(®) Technology platform for the development of antibody-dependent ... grants NKTT non-exclusive rights to research, develop, manufacture ...
Cached Biology Technology:Winners announced in 2009 Collegiate Inventors Competition 2Winners announced in 2009 Collegiate Inventors Competition 3Winners announced in 2009 Collegiate Inventors Competition 4Winners announced in 2009 Collegiate Inventors Competition 5Myriant Technologies LLC Announces Appointment of Science Advisory Board Members 2Myriant Technologies LLC Announces Appointment of Science Advisory Board Members 3BioWa and NKTT Announce Licensing of BioWa's POTELLIGENT(R) Technology For Use in Antibody Research and Development 2BioWa and NKTT Announce Licensing of BioWa's POTELLIGENT(R) Technology For Use in Antibody Research and Development 3